PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21687504-7	2011	Another putative S1P(1/3) receptor antagonist, VPC23019, does not inhibit S1P(3)-mediated vasoconstriction.	VPC23019	47-55	sphingosine-1-phosphate receptor 1	Mus musculus	17-20	
25930666-6	2015	hmSMC migration and DNA synthesis elicited by W6/32 were inhibited by the sphingosine kinase-1 (SK1) inhibitor dimethylsphingosine, the anti-S1P antibody Sphingomab and the S1PR1/R3 inhibitor VPC23019.	VPC23019	192-200	sphingosine-1-phosphate receptor 1	Mus musculus	173-178	
22913344-9	2013	All of these inhibitors except VPC23019 and nifedipine significantly reduced the S1P-induced tonic contractions.	VPC23019	31-39	sphingosine-1-phosphate receptor 1	Mus musculus	81-84	
19433984-3	2009	S1P stimulation of ERK was completely inhibited by an S1P1/3 subtype receptor antagonist (VPC23019), by a Gi protein inhibitor (pertussis toxin) and by a mitogen-activated protein kinase/ERK kinase inhibitor (PD98059).	VPC23019	90-98	sphingosine-1-phosphate receptor 1	Mus musculus	0-3	
30629456-3	2019	When ApoM-overexpressing HIGA mice were treated with VPC23019, an antagonist against S1P receptor 1 (S1P1) and 3 (S1P3), we observed that the protective effects of ApoM were reversed, whereas JTE013, an antagonist against S1P2, did not inhibit the effects.	VPC23019	53-61	sphingosine-1-phosphate receptor 1	Mus musculus	85-99	
17898040-5	2007	This protection with isoflurane was reversed by SK inhibitors (DMS and SKI-II) as well as an S1P(1) receptor antagonist (VPC23019).	VPC23019	121-129	sphingosine-1-phosphate receptor 1	Mus musculus	93-96	
32194396-11	2020	The S1P1 antagonist VPC23019 blocked the stimulatory effects of nmFGF1, whereas the S1P1 agonist FTY720 exerted effects comparable with those of nmFGF1.	VPC23019	20-28	sphingosine-1-phosphate receptor 1	Mus musculus	4-8	
30629456-3	2019	When ApoM-overexpressing HIGA mice were treated with VPC23019, an antagonist against S1P receptor 1 (S1P1) and 3 (S1P3), we observed that the protective effects of ApoM were reversed, whereas JTE013, an antagonist against S1P2, did not inhibit the effects.	VPC23019	53-61	sphingosine-1-phosphate receptor 1	Mus musculus	101-105	
29669385-6	2018	Treatment with VPC23019, an antagonist against S1P receptor 1 and 3, or LY294002, a PI3K inhibitor, partially reversed these protective properties arising from the overexpression of apoM.	VPC23019	15-23	sphingosine-1-phosphate receptor 1	Mus musculus	47-67